

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 637 633 A2

(12)

EUROPEAN PATENT APPLICATION(21) Application number: **94112272.3**(51) Int. Cl.⁶: **C12Q 1/56**(22) Date of filing: **05.08.94**(30) Priority: **06.08.93 JP 215177/93**(43) Date of publication of application:
08.02.95 Bulletin 95/06(84) Designated Contracting States:
AT BE CH DE ES FR GB IT LI

(71) Applicant: **NIPPON ZOKI PHARMACEUTICAL CO. LTD.**
1-2, 2-chome, Hiranomachi
Chuo-ku
Osaka (JP)

(72) Inventor: **Nishikawa, Katsumi, c/o Inst. of Bio-Active Science**
Nippon Zoki Pharm., Co., Ltd,
442-1, Kinashi
Yashiro-cho,
Kato-gun, Hyogo (JP)
Inventor: **Ishibashi, Nobuyuki, c/o Ono Greenery Factory**
Nippon Zoki Pharm., Co., Ltd,
1093, Minamiyama
Furukawa-cho,
Ono-shi,
Hyogo (JP)

(74) Representative: **Hansen, Bernd, Dr.**
Dipl.-Chem. et al
Hoffmann, Eitle & Partner
Patent- und Rechtsanwälte,
Postfach 81 04 20
D-81904 München (DE)

(54) **Method of determining activity of tested substance.**

(57) The present invention offers a method of measuring the activity of a tested substance which inhibits or promotes the production of the blood coagulation factor XII in an active form.

An activation reaction of a blood coagulation factor XII is initiated by adding a blood coagulation factor XII activator to the animal plasma in the presence of the tested substance, then the reaction is stopped and the blood coagulation factor XII in an active form produced in the above reaction is quantitatively determined.

FXIIa plays a very important role in the initiation stage in the intrinsic blood clotting system, fibrinolysis system and plasma kallikrein-kinin sys-

tem and, accordingly, also in the measuring method of the present invention, in which the activity of the tested substance having the inhibiting or promoting action on the production of FXIIa is very highly useful in screening the drugs related to blood clotting and fibrinolysis systems and those related to plasma kallikrein-kinin system such as, for example, blood pressure controlling agents, antiinflammatory agents, analgesics, antiallergic agents, etc.

EP 0 637 633 A2

Detailed Description of the Invention:

The present invention relates to a method of measuring the activity of a tested substance to the production of a blood coagulation factor XII in an active form and, more particularly, it relates to a method of measuring the activity of a substance which inhibits or promotes the production of the blood coagulation factor XII.

The blood coagulation factor XII (hereinafter abbreviated as an FXII) which is called a Hageman factor is a factor which is activated for the first time in the chain reaction of intrinsic blood clotting. An activated blood coagulation factor XII (the blood coagulation factor XII in an active form; hereinafter abbreviated as an FXIIa) activates the blood coagulation factor XII, then a series of the reaction system of intrinsic blood clotting as shown in (1) of Fig. 3 proceeds and, finally, an insoluble fibrin is produced whereupon the intrinsic blood clotting reaction is accomplished.

A series of the mechanisms for dissolving the fibrin clot is a fibrinolysis system and it has been knob that FXIIa participates in the initial phase of the fibrinolysis system. Thus, as shown in (2) of Fig. 3, plasmin which plays a main role in the fibrinolysis is present in plasma as an insoluble plasminogen but FXIIa is one of the activators which activate plasminogen. The reaction by which the fibrin clot is produced by coagulation of plasmin is the final stage of the fibrinolysis system.

In addition, activation of FXII is an initial stage of the plasma kallikrein-kinin system. In the plasma kallikrein-kinin system, it is believed that a series of enzymatic reaction systems are involved as a result of the activation of FXII by injury, invaded stimulation, etc. to the tissues *in vivo*. Thus, as shown in (3) of Fig. 3, the activated FXIIa acts on the plasma prekallikrein which is also present in the plasma, converts it to a plasma kallikrein which is an enzyme in an active form and then the plasma kallikrein acts on the high-molecular-weight kininogen (hereinafter abbreviated as an HK) to liberate bradykinin.

Kinins such as bradykinin which are the products in the kallikrein-kinin system exhibit various physiological activities such as decreasing the blood pressure due to dilation of peripheral blood vessels, promotion in permeability of blood vessels, contraction or relaxation of smooth muscle, induction of pain, induction of inflammation, migration of leucocytes, liberation of catecholamine from the adrenal cortex, etc. and are also known as mediators in acute inflammation including allergic reactions whereby their existence *in vivo* has a deep significance.

As such, FXIIa is a very important factor in the initial stage of the intrinsic blood clotting system,

fibrinolysis system and plasma kallikrein-kinin system. Accordingly, the substances affecting the production of FXIIa are expected to be useful as drugs in the areas of blood clotting and fibrinolysis and, in addition, there is a possibility that they can be used as antiinflammatory, analgesic and antiallergic drugs since bradykinin liberated in the plasma kallikrein-kinin system has various physiological activities as mentioned above.

Accordingly, the establishment of a method wherein the action and activity of a substance which inhibits or promotes the production of FXIIa which is an initiation factor of the intrinsic blood clotting system, fibrinolysis system and plasma kallikrein-kinin system can be measured in a simple, convenient, prompt and precise manner would be a very effective means for determining the action helpful in adjusting the bioregulations as mentioned above and also for developing such drugs.

An object of the present invention is to offer an *in vitro* method of measuring the activity of a tested substance which inhibits or promotes the production of FXIIa participating in various physiological reaction systems *in vivo* in a simple, convenient, prompt and precise manner.

Thus, the method of measuring the activity of a tested substance in accordance with the present invention is characterized in that an activation reaction of a blood coagulation factor XII is initiated by adding a blood coagulation factor XII activator to the animal plasma in the presence of the tested substance, then the reaction is stopped and the blood coagulation factor XII in an active form produced in the above reaction is quantitatively determined.

With respect to the plasma of animals which can be used in the measuring method of the present invention, the plasma of any animal will do so far as it has a blood clotting system and a plasma kallikrein-kinin system. For example, human plasma and plasma of cattle and experimental animals such as cows, sheep, pigs, horses, goats, monkeys, dogs, cats, rabbits, guinea pigs, hamsters, rats or mice may be utilized. Preferably, human plasma is used.

Such a plasma may be used in the form of a preparation manufactured by common methods. For example, a citric acid-added plasma prepared by collecting blood in the presence of citric acid followed by centrifuging may be used. Alternatively, freeze-dried plasma which is manufactured by conventional methods may be used. The animal plasma prepared as such may be used as it is or may be diluted, if desired, to control the reaction rate.

With reference to the FXII activator, any substance may be used so far as it exhibits an activating action for FXII such as, for example, glass,

kaolin, celite, collagen, homocystine, sodium urate, cell components of platelets and other cells, fibronectin, elaidic acid, quercetin, rutin, sulfated glycolipids, proteoglycan, mucopolysaccharides, sodium stearate, dextran sulfate, amylose sulfate, carrageenin and proteases which activate FXII by a restricted decomposition. They may be used either solely or jointly and the concentration of such FXII activators may be suitably selected.

The mixing reaction of the animal plasma, FXII activator and tested substance is preferably carried out at 0°C to 4°C so that the intrinsic inhibitor hardly acts and, in addition, the progress of the reaction can be easily controlled. The pH during the reaction may be suitably selected but, when human plasma is used, it is preferred to carry out the reaction at pH 7.0 to 9.0. Further, in order to set at an optimum reaction condition, salts such as sodium chloride, metal ions such as zinc ion and other additives and auxiliary agents which are commonly used in this art may be added to the reaction system.

The reaction time may be suitably selected depending upon the amount of the animal plasma, the concentrations of the FXII activators and the tested substance and the pH of the reaction solution, etc. When, however, production of the FXIIa is saturated, it is no longer possible to precisely evaluate the action of the tested substance. Accordingly, it is preferred to set the time before the production of FXIIa is saturated, i.e. within a time where a clear positive relationship between the reaction time and the produced FXIIa (e.g., preferably in terms of the evaluation, within a time where a substantially linearly proportional relationship exists between them) is available.

With respect to a method for stopping the above-mentioned reaction, it is preferred to use a substance (which stops the production of FXII in the reaction such as an inhibitor for activation of FXII such as polybren) and an inhibitor (which specifically inhibits the plasma kallikrein, preferably a plasma kallikrein inhibitor which does not substantially affect FXIIa such as SBTI [soy bean trypsin inhibitor; a trypsin inhibitor prepared from soy bean]) whereby the produced FXIIa can be quantitatively determined utilizing an enzymatic activity of FXIIa as a target using a substrate to FXIIa. The concentrations of those inhibitors may be suitably selected within such an extent that they do not substantially affect the FXIIa activity.

In the plasma kallikrein-kinin system, a feedback mechanism wherein the production of FXIIa is promoted by the produced plasma kallikrein has been known but the activity of a tested substance to the production of FXIIa by a pure FXIIa activation reaction which does not proceed through said feedback mechanism may be determined by the

present invention as well. In that case, (a) the plasma in which plasma prekallikrein is in a substantially deficient state prepared by such a means that an inhibitor which is specific to the plasma kallikrein such as the above-mentioned SBTI is previously added to the reaction system prior to the activation of FXII or (b) the prekallikrein-deficient plasma per se or that which is made in a substantially prekallikrein-deficient state by such a means that the plasma prekallikrein is removed from or inactivated in the normal plasma is used as the animal plasma whereby the present invention can be carried out.

The quantitative determination of the produced FXIIa can be carried out by conventional methods. For example, a method in which the measurement is conducted using a substrate to FXIIa utilizing an enzymatic activity of FXIIa may be used. A method using natural substrates such as plasma prekallikrein, blood coagulation factor XI or plasmin; coloring synthetic substrates such as D-Pro-Phe-Arg-pNA and D-Leu-Gly-Arg-pNA; or fluorescent synthetic substrates such as Boc-Glu(OBz)-Gly-Arg-MCA or Boc-Gln-Gly-Arg-MCA is often and commonly used because of its easiness and simplicity. Besides the above-mentioned measuring methods using the substrates, immunological measuring methods such as radioimmunoassay (RIA), enzyme immunoassay (EIA), etc., a quantitative analytic method utilizing chromatography and the like may be used.

(Examples)

The present invention will be further illustrated by way of the following examples.

To a solution comprising diluted human plasma, a certain amount of a substance to be tested (an analyte) and 25mM Tris hydrochloride buffer (pH: 8) containing 90 mM NaCl dextran sulfate was added to make its final concentration 2 micrograms/liter. The mixture was incubated in ice water for 15 minutes and then polyburene and SBTI were added thereto to make their final concentrations 200 micrograms/ml and 40 micrograms/ml, respectively. The reaction solution was incubated in a Tris hydrochloride buffer (pH: 8) together with 1 mM of D-Pro-Phe-Arg-pNA at 30°C for 30 minutes, the reaction was stopped by adding citric acid thereto, the mixture was centrifuged at 3,000 rpm for ten minutes and the absorbance (which corresponds to the produced amount of FXIIa) of the resulting supernatant liquid at 405 nm was measured.

Fig. 1 shows the changes in the absorbances when the incubating time in the above reaction is changed. In Fig. 1, the abscissa shows the incubating time (minutes) at 0°C while the ordinate shows the absorbance at 405 nm. In Fig. 1, FXIIa is

produced in almost linear increase with lapse of time until the incubating time becomes about 17 minutes and, therefore, it is preferred that the incubating time is to be set between 0 to 17 minutes.

Fig. 2 shows the result of the measurement of the inhibiting activity of four test drugs which are used as analgesic or antiallergic agents (indomethacin, ketoprofen, aminopyrine and ketotifen) to the FXIIa production in accordance with the measuring method of the present invention. In Fig. 2, the abscissa shows the concentration (mM) of the drugs tested while the ordinate shows the inhibiting rate (%) to the FXIIa production.

FXIIa plays a very important role in the initiation stage of intrinsic blood clotting system, fibrinolysis system and plasma kallikrein-kinin system. Accordingly, the method of the present invention in which the activity of a tested substance having an action of inhibiting or promoting the FXIIa production can be measured is very highly useful in screening the drugs related to blood clotting system and plasma kallikrein-kinin system such as blood pressure controlling agents, anti-inflammatory agents, analgesics, antiallergic agents, etc.

Further in accordance with the measuring method of the present invention, the feedback mechanism of the plasma kallikrein for the FXIIa production is secured whereby it is possible to screen the drugs which solely relate to the activating stage of FXII which is the initiation stage of the reaction in the intrinsic blood clotting system, fibrinolysis system, plasma kallikrein-kinin system, etc. Consequently, screening of the drugs based upon a clear and specific action mechanism is now possible and the present invention has a significant merit on the development of various new drugs.

Brief Explanation of the Drawings:

Fig. 1 is a graph showing the changes in the absorbance in various incubation time in the measuring method of the present invention.

Fig. 2 is a graph showing the result in the measurement of the inhibiting activity of some tested substances to the FXIIa production using the activity measuring method of the present invention.

Fig. 3 is a scheme for illustrating the regulation mechanism in vivo wherein FXIIa is participated.

Claims

1. A method of measuring the activity of a test substance, **characterized** by the following steps:
 - i) initiating an activation reaction of blood coagulation factor XII by adding a blood coagulation factor XII activator to animal

plasma in the presence of the test substance,

ii) stopping the reaction, and

iii) quantitatively determining the blood coagulation factor XII in its active form, produced in the above reaction.

2. A method according to claim 1 in which the production of the blood coagulation factor XII in an active form is stopped before this production becomes saturated.
3. A method according to claims 1 or 2 in which the blood coagulation factor XII in its active form is determined by using a substrate.
4. A method according to claim 3 in which the substrate is a synthetic substrate.
5. A method according to any one of claims 1 to 4 in which the blood coagulation factor XII is prevented from being produced in its active form via the plasma kallikrein-kinin feedback mechanism by either:
 - i) the addition of an inhibitor specific to plasma kallikrein prior to the activation of blood coagulation factor XII, or
 - ii) the removal of or deactivation of the plasma prekallikrein in the normal plasma, or
 - iii) using a prekallikrein-deficient plasma.
6. A method according to claim 5 in which the inhibitor used in (i) is SBTI.

Figure 1




Figure 2






Figure 3


(1) Intrinsic blood clotting system



(2) Fibrinolysis system



(3) Plasma kallikrein-kinin system



(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 637 633 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:

07.01.1998 Bulletin 1998/02

(51) Int. Cl.⁶: **C12Q 1/56**

(43) Date of publication A2:

08.02.1995 Bulletin 1995/06

(21) Application number: **94112272.3**

(22) Date of filing: **05.08.1994**

(84) Designated Contracting States:

AT BE CH DE ES FR GB IT LI

(30) Priority: **06.08.1993 JP 215177/93**

(71) Applicant:

**NIPPON ZOKI PHARMACEUTICAL CO. LTD.
Osaka (JP)**

(72) Inventors:

• **Nishikawa, Katsumi,
c/o Inst.of Bio-Active Science
Yashiro-cho, Katoh-gun, Hyogo (JP)**

• **Ishibashi, Nobuyuki,**

c/o Ono Greenery Factory

Furukawa-cho, Ono-shi, Hyogo (JP)

(74) Representative:

Hansen, Bernd, Dr. Dipl.-Chem. et al

Hoffmann Eitle,

Patent- und Rechtsanwälte,

Postfach 81 04 20

81904 München (DE)

(54) Method of determining activity of tested substance

(57) The present invention offers a method of measuring the activity of a tested substance which inhibits or promotes the production of the blood coagulation factor XII in an active form.

An activation reaction of a blood coagulation factor XII is initiated by adding a blood coagulation factor XII activator to the animal plasma in the presence of the tested substance, then the reaction is stopped and the blood coagulation factor XII in an active form produced in the above reaction is quantitatively determined.

FXIIa plays a very important role in the initiation stage in the intrinsic blood clotting system, fibrinolysis system and plasma kallikrein-kinin system and, accordingly, also in the measuring method of the present invention, in which the activity of the tested substance having the inhibiting or promoting action on the production of FXIIa is very highly useful in screening the drugs related to blood clotting and fibrinolysis systems and those related to plasma kallikrein-kinin system such as, for example, blood pressure controlling agents, anti-inflammatory agents, analgesics, antiallergic agents, etc.

EP 0 637 633 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 94 11 2272

DOCUMENTS CONSIDERED TO BE RELEVANT					
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)		
Y	EP 0 259 857 A (NIPPON ZOKI PHARMACEUTICAL CO. LTD.) * the whole document *	1-6	C12Q1/56		
Y	EP 0 078 764 A (PENTAPHARM AG.) * the whole document *	1-6			
Y	US 4 882 272 A (C. F. SCOTT ET AL.) * the whole document *	1-6			
Y	H. U. BERGMEYER (EDITOR-IN-CHIEF): "Methods of Enzymatic Analysis, Vol. V." 1984, VERLAG CHEMIE GMBH., WEINHEIM, DE XP002046938 014041 * page 316 - page 351 * * page 394 - page 399 *	1-6			
A	EP 0 190 766 A (BOEHRINGER MANNHEIM GMBH.) * the whole document *	1-6			
A	WO 91 17258 A (CETUS CORPORATION) * the whole document *	1-6	<table border="1"> <thead> <tr> <th>TECHNICAL FIELDS SEARCHED (Int.Cl.6)</th> </tr> </thead> <tbody> <tr> <td>C12Q</td> </tr> </tbody> </table>	TECHNICAL FIELDS SEARCHED (Int.Cl.6)	C12Q
TECHNICAL FIELDS SEARCHED (Int.Cl.6)					
C12Q					
The present search report has been drawn up for all claims					
Place of search THE HAGUE		Date of completion of the search 14 November 1997	Examiner Griffith, G		
<table border="0"> <tr> <td style="vertical-align: top;"> CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document </td> <td style="vertical-align: top;"> T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document </td> </tr> </table>				CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document	T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document	T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document				

EPO FORM 1503 03.82 (P04C01)